MedAssets in brief
MedAssets is an unlisted company, based in Alpharetta, USA. In the year to December 2014 it had sales of $720 M and a net loss of $20 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About MedAssets
MedAssets, Inc. was an American healthcare performance improvement company. It provided products and services to 4,400 hospitals and 122,000 non-acute healthcare providers.
The Alpharetta, Georgia based company had 15 offices across the United States. States with a MedAssets location included California, Colorado, Georgia, New Jersey, Texas, and Washington.
In early 2016, MedAssets was split into two companies and was sold out. The company no longer exists in its original form, although some of its products exist under other brand names under various companies including nThrive (now FinThrive).
From Wikipedia: read the full article · text available under CC BY-SA 4.0
MedAssets timeline
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2007
- 🔔Initial public offeringFinal prospectus filed with the SEC on 13 December 2007; shares registered for exchange trading on 10 December 2007.
Events of MedAssets from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about MedAssets
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 27 January 2016 (Form 8-K).
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -2.8%
- Operating margin
- 6.5%
- Return on equity
- -4.6%
- Liabilities / assets
- 74.0%
- Net debt
- $839M
- Revenue growth
- +5.9%
- R&D / revenue
- 4.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2014 | $720M | +5.9% | $46M | $-20M | -2.8% |
| Dec 2013 | $680M | +6.3% | $91M | $27M | 4.0% |
| Dec 2012 | $640M | +10.7% | $85M | $-7M | -1.1% |
| Dec 2011 | $578M | +47.8% | $42M | $-15M | -2.7% |
| Dec 2010 | $391M | +14.7% | $-20M | $-32M | -8.2% |
| Dec 2009 | $341M | — | $50M | $20M | 5.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2014 | $139M | $63M | $76M | $-0.34 | — |
| Dec 2013 | $153M | $59M | $94M | $0.45 | — |
| Dec 2012 | $158M | $66M | $91M | $-0.12 | — |
| Dec 2011 | $124M | $17M | $107M | $-0.27 | — |
| Dec 2010 | $106M | $13M | $93M | $-0.57 | — |
| Dec 2009 | $60M | $12M | $49M | $0.34 | — |
SEC filings
- Jan 27, 20168-KCurrent reportMaterial agreement · Agreement ended · Acquisition or disposal completed · New financial obligation · Listing notice · Change in control · Bylaws amended
- Jan 14, 20168-KCurrent reportShareholder vote · Other events
- Dec 9, 20158-KCurrent reportOther events
- Nov 6, 201510-QQuarterly report · period to Sep 2015
- Nov 4, 20158-KCurrent reportOther events
- Nov 2, 20158-KCurrent reportOther events
- Nov 2, 20158-KCurrent reportMaterial agreement · Bylaws amended · Other events
- Nov 2, 20158-KCurrent reportResults of operations
- Sep 30, 20158-KCurrent reportRestructuring costs · Impairment · Regulation FD disclosure
- Sep 8, 20158-KCurrent reportDirectors or officers changed · Other events
- Aug 4, 201510-QQuarterly report · period to Jun 2015
- Aug 4, 20158-KCurrent reportRegulation FD disclosure
Official filings of MedAssets with the US Securities and Exchange Commission.
Annual results
- Revenue
- $720 M
- Operating income
- $46 M
- Net income
- $-20 M
For year ending December-2014 · source: SEC filing
Balance sheet
- Total assets
- $1.7 B
- Total liabilities
- $1.3 B
- Total equity
- $446 M
As of December-2014
Insider trading at MedAssets#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Rand A. BallardChief Customer Officer, Director | Disposal to the company | -116,510 | — | — | 0 | Form 4 |
| filed | Anthony Colaluca Jr.Chief Financial Officer | Disposal to the company | -17,660 | — | — | 0 | Form 4 |
| filed | R. Halsey WiseChairman and CEO, Director | Disposal to the company | -299,386 | — | — | 0 | Form 4 |
| filed | C. A. PiccoloDirector | Disposal to the company | -150,933 | — | — | 0 | Form 4 |
| filed | Kevin M. TwomeyDirector | Disposal to the company | -4,365 | — | — | 0 | Form 4 |
| filed | Terrence J. MulliganDirector | Disposal to the companyindirect | -139,570 | — | — | 0 | Form 4 |
| filed | Charles O. GarnerChief Financial Officer | Disposal to the company | -79,144 | — | — | 0 | Form 4 |
| filed | Amy AmickPresident, RCM Segment | Disposal to the company | -10,704 | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: MedAssets#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2015 | Q3 2015 | $16.5M |
| Q2 2015 | Q2 2015 | $8.7M |
| Q1 2015 | Q1 2015 | $3.8M |
| Q4 2014 | Q4 2014 | $0.2M |
| Q3 2014 | Q3 2014 | $0.3M |
| Q2 2014 | Q2 2014 | $29.8M |
| Q1 2014 | Q1 2014 | $15.7M |
| Q4 2012 | Q4 2012 | $0M |
| Q3 2012 | Q3 2012 | $0M |
| Q2 2012 | Q2 2012 | $0M |
| Q1 2012 | Q1 2012 | $0.6M |
| Q4 2011 | Q4 2011 | $4.2M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
MedAssets scorecard#
Passes 6 of the 15 checks that could be worked out: strongest in growth (3 of 5), weakest in profitability (0 of 4). Fiscal year 2014.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth3 of 5
- ✓Revenue grew in the newest year5.8%Revenue up 5.8% in fiscal 2014.
- ✓Revenue up more than 5% a year over three years7.6%7.6% a year over the three years to fiscal 2014.
- –Faster growth over three years than its peers' medianToo few peers for a median.
- ✗Earnings per share grew in the newest year-0.34 vs 0.45Diluted EPS -0.34 in fiscal 2014 against 0.45 the year before (report's currency).
- ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2014 against $20 M in 2009.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2014.
Profitability0 of 4
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2014.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2014.
- –Operating margin above its peers' medianToo few peers for a median.
- ✗Return on equity above 15%-4.4%-4.4% in fiscal 2014.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier6.5%6.5% in fiscal 2014 against 7.3% in 2011.
Financial health1 of 4
- ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.66 at the end of fiscal 2014.
- ✗Debt below equity1.9×Debt to equity 1.91 at the end of fiscal 2014.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times1.0×Operating income 1.0 times interest in fiscal 2014.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2014.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns2 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-2.2%Diluted shares down 2.2% in fiscal 2014.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- ✓Free cash flow covers dividends and buybacks$76 MFree cash flow $76 M against $46 M paid out in fiscal 2014.
Worked out from the statements as filed (sec), the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
MedAssets: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 | FY 2011to Dec 31, 2011 | FY 2010to Dec 31, 2010 | FY 2009to Dec 31, 2009 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 720+5.9%100% | 680+6.3%100% | 640+10.7%100% | 578+47.8%100% | 391+14.7%100% | 341—100% | |
| Cost of revenue | 172+13.1%23.9% | 152+9.6%22.3% | 139+13.8%21.7% | 122+20.9%21.1% | 101+34.9%25.7% | 75—21.9% | |
| Research and development | 31+0.8%4.3% | 31+8.4%4.5% | 28+6.2%4.4% | 27+34.0%4.6% | 20+5.4%5.1% | 19—5.6% | |
| Selling and marketing | 67+9.8%9.4% | 61+1.6%9.0% | 60+6.0%9.4% | 57+22.0%9.9% | 47+3.2%11.9% | 45—13.3% | |
| General and administrative | 238+2.5%33.0% | 232+6.2%34.1% | 218+7.4%34.1% | 203+63.3%35.1% | 124+12.4%31.8% | 111—32.4% | |
| Total costs and expenses | 674+14.3%93.5% | 590+6.3%86.7% | 555+3.5%86.7% | 536+30.5%92.7% | 411+41.3%105% | 291—85.2% | |
| Operating income | 46−48.8%6.5% | 91+6.5%13.3% | 85+102%13.3% | 42—7.3% | −20−139%−5.0% | 50—14.8% | |
| Interest expense and finance costs | 46−2.9%6.3% | 47−29.0%6.9% | 66−7.1%10.3% | 71+158%12.3% | 28+51.9%7.0% | 18—5.3% | |
| Other non-operating income (expense) | 0.3+9.8%0.0% | 0.3−58.1%0.0% | 0.7−81.1%0.1% | 3.6+457%0.6% | 0.7+55.9%0.2% | 0.4—0.1% | |
| Income before tax | 1.2−97.3%0.2% | 44—6.5% | −8.4—−1.3% | −25—−4.4% | −46−242%−11.9% | 33—9.6% | |
| Income tax | 22+29.5%3.0% | 17—2.5% | −1.5—−0.2% | −9.9—−1.7% | −14−211%−3.6% | 13—3.8% | |
| Net income attributable to shareholders | −20−174%−2.8% | 27—4.0% | −6.9—−1.1% | −15—−2.7% | −32−261%−8.2% | 20—5.8% | |
| Earnings per share, basic | -0.34−174%— | 0.46—— | -0.12—— | -0.27—— | -0.57−258%— | 0.36—— | |
| Earnings per share, diluted | -0.34−176%— | 0.45—— | -0.12—— | -0.27—— | -0.57−268%— | 0.34—— | |
| Shares, weighted average (basic) | 60+0.2%— | 60+3.9%— | 57+0.3%— | 57+1.5%— | 56+2.9%— | 55—— | |
| Shares, weighted average (diluted) | 60−2.2%— | 61+6.5%— | 57+0.3%— | 57+1.5%— | 56−2.5%— | 58—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 12+334%0.7% | 2.8−79.7%0.2% | 14−78.2%0.8% | 63+34.4%3.5% | 47+752%2.5% | 5.5r5.5—0.7% | |
| Receivables | 128+45.8%7.4% | 88−9.0%5.4% | 96−7.4%5.7% | 104+4.0%5.8% | 100+47.9%5.4% | 68—8.7% | |
| Other current assets | 31+27.0%1.8% | 24+10.4%1.5% | 22+17.9%1.3% | 18−6.7%1.0% | 20—1.1% | — | |
| Current assets | 176+48.0%10.3% | 119−16.8%7.4% | 143−28.8%8.5% | 201+8.7%11.2% | 185+92.5%10.0% | 96—12.3% | |
| Property, plant and equipment | 170+8.0%9.9% | 158+17.4%9.8% | 134+32.4%8.0% | 101+30.5%5.7% | 78+41.4%4.2% | 55—7.1% | |
| Goodwill | 1,058+3.0%61.6% | 1,0280.0%63.7% | 1,0280.0%61.2% | 1,028−0.8%57.3% | 1,036+102%56.1% | 512—65.7% | |
| Other intangible assets | 276+3.4%16.1% | 267−19.0%16.6% | 330−18.1%19.7% | 403−16.7%22.5% | 484+407%26.3% | 96—12.3% | |
| Total assets | 1,719+6.5%100% | 1,614−3.8%100% | 1,678−6.5%100% | 1,795−2.7%100% | 1,845+137%100% | 779—100% | |
| Accounts payable | 27+11.8%1.6% | 24−5.6%1.5% | 25+20.3%1.5% | 21+17.0%1.2% | 18+109%1.0% | 8.7—1.1% | |
| Debt due within a year | 30+90.9%1.7% | 160.0%1.0% | 16+144%0.9% | 6.4r−6.4—0.4% | −6.4—−0.3% | — | |
| Current liabilities | 267+22.6%15.5% | 217−3.6%13.5% | 225−29.2%13.4% | 318+12.4%17.7% | 283+185%15.3% | 99—12.8% | |
| Long-term debt | 851+13.7%49.5% | 749−13.9%46.4% | 870−3.1%51.8% | 897−5.9%50.0% | 954—51.7% | — | |
| Total liabilities | 1,272+13.2%74.0% | 1,124−9.7%69.6% | 1,245−9.6%74.2% | 1,376−2.4%76.7% | 1,410+313%76.4% | 341—43.8% | |
| Retained earnings | −248—−14.4% | −228—−14.1% | −255—−15.2% | −249—−13.8% | −233—−12.6% | −201—−25.8% | |
| Shareholders' equity | 446−8.8%26.0% | 490+13.0%30.4% | 434+3.6%25.8% | 419−3.9%23.3% | 436−0.4%23.6% | 437—56.2% | |
| Total liabilities and equity | 1,719+6.5%100% | 1,614−3.8%100% | 1,678−6.5%100% | 1,795−2.7%100% | 1,845+137%100% | 779—100% | |
| Shares outstanding | 60−2.5%— | 62+4.1%— | 59+2.5%— | 58−0.9%— | 58+3.0%— | 57—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 18+23.1%2.5% | 14+40.9%2.1% | 10+105%1.6% | 5.0−56.3%0.9% | 11−31.0%2.9% | 17—4.9% | |
| Cash from operating activities | 139−9.1%19.3% | 153−3.1%22.5% | 158+27.1%24.7% | 124+17.3%21.5% | 106+75.6%27.1% | 60—17.7% | |
| Capital expenditure | −63—−8.8% | −59r−18—−8.6% | −66r−26—−10.4% | −17—−2.9% | −13—−3.3% | −12—−3.5% | |
| Acquisitions, net of cash acquired | −141—−19.6% | — | — | — | −749—−191% | −18—−5.4% | |
| Cash from investing activities | −205—−28.4% | −59—−8.6% | −66—−10.4% | −49—−8.5% | −780—−199% | −46—−13.6% | |
| Shares issued | 3.6−64.3%0.5% | 10+31.7%1.5% | 7.7+289%1.2% | 2.0−81.5%0.3% | 11+2.8%2.7% | 10—3.0% | |
| Shares bought back | −46—−6.4% | — | −0.6—−0.1% | −5.0—−0.9% | — | — | |
| Cash from financing activities | 75—10.4% | −105—−15.4% | −141—−22.0% | −59−108%−10.2% | 715—183% | −14—−4.0% | |
| Change in cash | 9.3—1.3% | −11—−1.6% | −49−405%−7.7% | 16−61.0%2.8% | 41+59810%10.6% | 0.1—0.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2015 | Q3 FY2015to Sep 30, 2015 | Q2 FY2015to Jun 30, 2015 | Q1 FY2015to Mar 31, 2015 | Q4 FY2014to Dec 31, 2014 | Q3 FY2014to Sep 30, 2014 | Q2 FY2014to Jun 30, 2014 | Q1 FY2014to Mar 31, 2014 | Q4 FY2013to Dec 31, 2013 | Q3 FY2013to Sep 30, 2013 | Q2 FY2013to Jun 30, 2013 | Q1 FY2013to Mar 31, 2013 | Q4 FY2012to Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 764+10.4%100% | 190+8.1%100% | 190+8.6%100% | 186+8.6%100% | 198+16.3%100% | 176+5.6%100% | 175+2.7%100% | 171−1.1%100% | 170+4.1%100% | 166—100% | 171—100% | 173—100% | 164—100% | |
| Cost of revenue | 190+17.0%24.8% | 48+13.1%25.3% | 47+16.8%24.7% | 43+14.7%23.1% | 52*+23.1%26.0% | 42+11.0%24.2% | 40+7.6%23.0% | 37+9.2%21.9% | 42*+10.3%24.6% | 38—23.0% | 37—22.0% | 34—19.8% | 38*—23.2% | |
| Gross profit | — | — | — | — | 147+14.1%74.0% | 133+4.0%75.8% | 135+1.4%77.0% | 133−3.7%78.1% | 129+2.2%75.4% | 128—77.0% | 133—78.0% | 139—80.2% | 126—76.8% | |
| Research and development | 33+12.5%4.3% | 8.2+1.1%4.3% | 7.5+12.2%3.9% | 8.4+13.6%4.5% | 9.0*+24.4%4.5% | 8.1+13.0%4.6% | 6.6−16.7%3.8% | 7.4−13.0%4.3% | 7.2*−6.2%4.2% | 7.2—4.3% | 8.0—4.7% | 8.5—4.9% | 7.7*—4.7% | |
| Selling and marketing | 78+20.1%10.2% | 17+19.9%9.0% | 24+15.1%12.5% | 20+28.4%10.5% | 17*+18.9%8.7% | 14+10.7%8.1% | 21+2.1%11.8% | 15+10.6%8.9% | 15*+5.6%8.5% | 13—7.8% | 20—11.9% | 14—8.0% | 14*—8.4% | |
| General and administrative | 250+7.4%32.7% | 64+11.8%33.9% | 59−0.2%31.2% | 64+9.7%34.7% | 62*+8.4%31.1% | 58−2.6%32.8% | 60+4.1%33.9% | 59+0.3%34.4% | 57*+8.2%33.4% | 59—35.5% | 57—33.5% | 59—33.9% | 53*—32.1% | |
| Total costs and expenses | 740+23.9%96.8% | 182+20.1%95.6% | 167+9.0%87.6% | 168+15.1%90.6% | 223*+52.3%113% | 151+5.1%86.0% | 153+1.8%87.3% | 146−1.8%85.5% | 147*+4.9%86.0% | 144—86.4% | 150—88.1% | 149—86.1% | 140*—85.4% | |
| Operating income | 24−74.5%3.2% | 8.4−65.6%4.4% | 24+5.8%12.4% | 17−29.7%9.4% | −25*−205%−12.7% | 25+8.6%14.0% | 22+9.4%12.7% | 25+3.3%14.5% | 24*−0.7%14.0% | 23—13.6% | 20—11.9% | 24—13.9% | 24*—14.6% | |
| Interest expense and finance costs | 47+4.9%6.2% | 12+1.9%6.1% | 12+6.3%6.2% | 12+6.2%6.4% | 12*+5.1%6.0% | 11−4.0%6.5% | 11−10.2%6.3% | 11−1.6%6.5% | 11*−25.8%6.7% | 12—7.1% | 12—7.3% | 11—6.6% | 15*—9.4% | |
| Other non-operating income (expense) | −0.2−193%−0.0% | −0.1−138%−0.1% | −0.1−455%−0.1% | 0.1+6.9%0.0% | −0.0*—−0.0% | 0.3+131%0.2% | 0.0−88.8%0.0% | 0.1+41.5%0.0% | −0.1*−163%−0.1% | 0.1—0.1% | 0.3—0.2% | 0.0—0.0% | 0.2*—0.1% | |
| Income before tax | −23−146%−3.0% | −3.2−124%−1.7% | 12+4.0%6.1% | 5.6−59.0%3.0% | −37*−402%−18.7% | 13+23.6%7.7% | 11+35.5%6.4% | 14+7.7%8.0% | 12*—7.2% | 11—6.5% | 8.3—4.8% | 13—7.3% | −19*—−11.8% | |
| Income tax | 12−42.9%1.6% | −1.0−117%−0.5% | 5.3+16.0%2.8% | 2.3−62.4%1.2% | 5.3*+16.9%2.7% | 5.7+43.4%3.3% | 4.6+44.8%2.6% | 6.0+20.1%3.5% | 4.5*—2.7% | 4.0—2.4% | 3.2—1.9% | 5.0—2.9% | −4.9*—−3.0% | |
| Net income attributable to shareholders | −35−217%−4.6% | −2.2−129%−1.2% | 6.3−4.3%3.3% | 3.4−56.3%1.8% | −42−647%−21.4% | 7.7+12.1%4.4% | 6.6+29.7%3.8% | 7.7−0.3%4.5% | 7.8—4.5% | 6.9—4.1% | 5.1—3.0% | 7.7—4.5% | −14—−8.8% | |
| Earnings per share, basic | -0.58−216%— | -0.04−131%— | 0.110.0%— | 0.06−53.8%— | -0.71−646%— | 0.13+8.3%— | 0.11+22.2%— | 0.130.0%— | 0.13—— | 0.12—— | 0.09—— | 0.13—— | -0.25—— | |
| Earnings per share, diluted | -0.59−220%— | -0.04−131%— | 0.10−9.1%— | 0.06−50.0%— | -0.71−646%— | 0.13+18.2%— | 0.11+37.5%— | 0.12−7.7%— | 0.13—— | 0.11—— | 0.08—— | 0.13—— | -0.25—— | |
| Shares, weighted average (basic) | 59+0.1%— | 59+0.1%— | 60+0.2%— | 60−1.5%— | — | 59−0.9%— | 60+0.6%— | 61+2.8%— | — | 60—— | 59—— | 59—— | — | |
| Shares, weighted average (diluted) | 59−2.0%— | 59−2.0%— | 61+0.2%— | 61−1.9%— | — | 61−1.3%— | 61+0.5%— | 62+2.1%— | — | 61—— | 61—— | 60—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0—0.0% | 0−100%0.0% | 10+71.1%0.6% | 19—1.1% | 12+334%0.7% | 14—0.8% | 6.0+739%0.4% | 0−100%0.0% | 2.8−79.7%0.2% | 0—0.0% | 0.7—0.0% | 8.5—0.5% | 14—0.8% | |
| Receivables | 120—7.4% | 120+9.2%7.4% | 129+32.0%7.7% | 124+22.7%7.3% | 128+45.8%7.4% | 110+20.6%6.3% | 98+2.4%6.1% | 101+7.8%6.3% | 88−9.0%5.4% | 91—5.6% | 96—5.8% | 94—5.6% | 96—5.7% | |
| Other current assets | 25—1.5% | 25+3.0%1.5% | 24−8.6%1.5% | 27+10.9%1.6% | 31+27.0%1.8% | 24−2.0%1.4% | 27+24.4%1.7% | 24−6.0%1.5% | 24+10.4%1.5% | 25—1.5% | 22—1.3% | 26—1.5% | 22—1.3% | |
| Current assets | 151—9.3% | 151+1.8%9.3% | 170+28.8%10.2% | 175+37.3%10.3% | 176+48.0%10.3% | 148+17.1%8.5% | 132+7.3%8.2% | 128−7.8%8.0% | 119−16.8%7.4% | 127—7.7% | 123—7.5% | 139—8.3% | 143—8.5% | |
| Property, plant and equipment | 154—9.5% | 154−5.2%9.5% | 165+2.8%9.8% | 167+6.9%9.8% | 170+8.0%9.9% | 163+4.6%9.3% | 160+5.4%10.0% | 157+10.7%9.7% | 158+17.4%9.8% | 155—9.5% | 152—9.3% | 141—8.5% | 134—8.0% | |
| Goodwill | 1,058—65.1% | 1,058−4.5%65.1% | 1,058+3.0%63.2% | 1,058+3.0%62.3% | 1,058+3.0%61.6% | 1,108+7.8%63.3% | 1,0280.0%64.2% | 1,0280.0%64.0% | 1,0280.0%63.7% | 1,028—62.9% | 1,028—62.6% | 1,028—61.8% | 1,028—61.2% | |
| Other intangible assets | 232—14.2% | 232−20.5%14.2% | 246+2.9%14.7% | 261+3.1%15.4% | 276+3.4%16.1% | 291+3.2%16.6% | 239−19.5%15.0% | 253−19.2%15.8% | 267−19.0%16.6% | 282—17.3% | 298—18.1% | 314—18.9% | 330—19.7% | |
| Total assets | 1,627—100% | 1,627−7.1%100% | 1,674+4.6%100% | 1,698+5.7%100% | 1,719+6.5%100% | 1,751+7.1%100% | 1,601−2.5%100% | 1,607−3.4%100% | 1,614−3.8%100% | 1,635—100% | 1,642—100% | 1,663—100% | 1,678—100% | |
| Accounts payable | 19—1.2% | 19−10.4%1.2% | 17+3.9%1.0% | 18−7.8%1.1% | 27+11.8%1.6% | 21+24.6%1.2% | 17−42.3%1.0% | 20+2.3%1.2% | 24−5.6%1.5% | 17—1.0% | 29—1.8% | 19—1.2% | 25—1.5% | |
| Debt due within a year | 26—1.6% | 26+31.0%1.6% | 25+33.6%1.5% | 23−30.0%1.4% | 30+90.9%1.7% | 20+30.2%1.2% | 19+20.2%1.2% | 33+115%2.1% | 160.0%1.0% | 16—0.9% | 16—0.9% | 16—0.9% | 16—0.9% | |
| Current liabilities | 275—16.9% | 275+14.9%16.9% | 263+25.1%15.7% | 248+6.0%14.6% | 267+22.6%15.5% | 240+9.3%13.7% | 211−4.4%13.2% | 234+17.6%14.6% | 217−3.6%13.5% | 219—13.4% | 220—13.4% | 199—12.0% | 225—13.4% | |
| Long-term debt | 763—46.9% | 763−13.3%46.9% | 807+5.1%48.2% | 844+15.1%49.7% | 851+13.7%49.5% | 880+13.1%50.2% | 768−4.8%48.0% | 734−13.8%45.7% | 749−13.9%46.4% | 778—47.6% | 807—49.1% | 851—51.1% | 870—51.8% | |
| Total liabilities | 1,184—72.8% | 1,184−6.4%72.8% | 1,219+8.0%72.8% | 1,246+11.2%73.4% | 1,272+13.2%74.0% | 1,265+9.5%72.3% | 1,128−4.6%70.5% | 1,121−7.7%69.8% | 1,124−9.7%69.6% | 1,156—70.7% | 1,183—72.0% | 1,214—73.0% | 1,245—74.2% | |
| Retained earnings | −241—−14.8% | −241—−14.8% | −239—−14.3% | −245—−14.4% | −248—−14.4% | −206—−11.8% | −214—−13.4% | −220—−13.7% | −228—−14.1% | −236—−14.4% | −243—−14.8% | −248—−14.9% | −255—−15.2% | |
| Shareholders' equity | 443—27.2% | 443−8.8%27.2% | 455−3.6%27.2% | 452−7.0%26.6% | 446−8.8%26.0% | 486+1.4%27.7% | 472+2.8%29.5% | 486+8.2%30.2% | 490+13.0%30.4% | 479—29.3% | 459—28.0% | 449—27.0% | 434—25.8% | |
| Total liabilities and equity | 1,627—100% | 1,627−7.1%100% | 1,674+4.6%100% | 1,698+5.7%100% | 1,719+6.5%100% | 1,751+7.1%100% | 1,601−2.5%100% | 1,607−3.4%100% | 1,614−3.8%100% | 1,635—100% | 1,642—100% | 1,663—100% | 1,678—100% | |
| Shares outstanding | 59—— | 59−1.6%— | 60−0.2%— | 60−1.3%— | 60−2.5%— | 60−2.6%— | 60−1.5%— | 61+0.5%— | 62+4.1%— | 62—— | 61—— | 61—— | 59—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 20+14.1%2.6% | 5.6+16.2%2.9% | 5.4−3.5%2.8% | 5.7+33.2%3.1% | 3.1*+16.0%1.6% | 4.8+10.3%2.7% | 5.6+39.4%3.2% | 4.3+26.1%2.5% | 2.7*+8.7%1.6% | 4.4—2.6% | 4.0—2.3% | 3.4—2.0% | 2.5*—1.5% | |
| Cash from operating activities | 187+34.1%24.4% | 62*+37.8%32.8% | 47*+41.1%24.5% | 35+95.1%18.6% | 43*−0.3%21.7% | 45*+7.2%25.8% | 33*−34.0%18.8% | 18+1.4%10.4% | 43*−14.2%25.3% | 42*—25.4% | 50*—29.3% | 17—10.1% | 50*—30.6% | |
| Capital expenditure | −60—−7.8% | −3.1*—−1.6% | −1.8*—−1.0% | −1.3—−0.7% | −53r−23*—−27.0% | −2.6r−12*—−1.5% | −5.5r−26*—−3.1% | −1.7—−1.0% | −12*—−7.3% | −22*—−13.4% | −4.6*—−2.7% | −0.7—−0.4% | −14*—−8.8% | |
| Acquisitions, net of cash acquired | — | — | — | — | −3.0*—−1.5% | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −62—−8.1% | −13*—−7.0% | −12*—−6.1% | −11—−6.1% | −26*—−13.1% | −151*—−85.7% | −18*—−10.2% | −10—−5.9% | −12*—−7.3% | −22*—−13.4% | −15*—−8.9% | −9.0—−5.2% | −24*—−14.4% | |
| Shares issued | 1.6−54.8%0.2% | 0.4*−45.8%0.2% | 0.3*−57.0%0.2% | 0.6−65.8%0.3% | 0.2*+13.2%0.1% | 0.8*−86.9%0.5% | 0.8*−12.2%0.5% | 1.8−35.6%1.0% | 0.2*−91.6%0.1% | 6.3*—3.8% | 0.9*—0.5% | 2.7—1.6% | 2.4*—1.5% | |
| Shares bought back | −29—−3.8% | −16*—−8.7% | −8.7*—−4.5% | −3.8—−2.0% | −0.2*—−0.1% | −0.3*—−0.2% | −30*—−17.0% | −16—−9.2% | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | −138−310%−18.1% | −59*−152%−31.2% | −44*—−23.0% | −16—−8.8% | −19*—−9.5% | 113*—64.4% | −9.1*—−5.2% | −10—−6.1% | −28*—−16.4% | −21*—−12.5% | −43*—−25.0% | −14—−7.9% | −21*—−12.9% | |
| Change in cash | −14−200%−1.8% | −10*−230%−5.4% | −8.7*−245%−4.6% | 6.9—3.7% | −1.8*−164%−0.9% | 7.9*—4.5% | 6.0*—3.4% | −2.8—−1.6% | 2.8*−49.3%1.6% | −0.7*—−0.4% | −7.8*—−4.6% | −5.2—−3.0% | 5.5*—3.4% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2015. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at MedAssets#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Impairment 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 2 · Directors and officers 9 · Material agreement 3 · Agreement ended 1 · New debt 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedMaterial agreementAgreement endedNew debtShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementBylaws or fiscal year changed | 8-K | |
| ImpairmentRestructuring | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completed | 8-K | |
| New debt | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jan 27, 2016
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015 | · | · | · | · | · | · | · | · | 180 | · | · | · | 180 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 180 people (5% of workforce) | Restructuring planSEC 8-K | “As part of this cost reduction program, the Company plans to reduce its workforce by approximately 180 full-time employees, or about 5% of its total headcount by year-end 2015.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Questions, comparisons and similar companies#
Questions people ask
Sources and freshness
- Annual results:
- For year ending December-2014
- Balance sheet:
- As of December-2014
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at MedAssets? Verify and update this profile — free
Show MedAssets's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.